Sagent Pharmaceuticals and Itochu Chemical Frontier Corporation Announce Development and Manufacturing Collaboration
News Oct 22, 2008
Sagent Pharmaceuticals, Inc. and Itochu Chemical Frontier Corporation (ICF) have announced finalization of a development and supply collaboration. Under the agreement, ICF will supply injectable products for which Sagent will obtain U.S. regulatory approval and market in the United States.
"We are extremely pleased to partner with a global company of Itochu's caliber and skills on these exciting product opportunities," said Jeffrey M. Yordon, CEO, founder and chairman of the board of Sagent Pharmaceuticals, Inc.
"Sagent is committed to expanding its network of worldwide strategic partnerships to offer the most diverse and extensive pipeline of the highest quality injectable products to our hospital focused customers and we look forward to including ICF amongst our partners."
"ICF looks forward to rapidly expanding our presence in the U.S. market," said Jun Sato, ICF's president and chief executive officer. "We believe that this collaboration combining ICF's experience in the Japanese market with Sagent's U.S. focused injectable selling and marketing capabilities is an optimal path toward achieving this objective."
New Chemical Synthesis Process: Synergy of Two Catalysts in One FlaskNews
Researchers report the one-step synthesis of a ketone from an aldehyde by the combination of thiazolium N-heterocyclic carbene and palladium/bisphosphine catalysts in one flask. The two catalysts function in a synergistic manner. This study is expected to lead to new synthesis processes of precursor compounds for medications.READ MORE
Synthesis of Drug-Like Molecules Simplified Using New Cross-Coupling MethodNews
Researchers have designed a new molecule-building method. The technique, described recently in the journal Science, paves the way toward other new chemical reactions and facilitates the synthesis of pharmaceutically-relevant molecules.READ MORE
Domainex Appoints Dr Bodo Spori as Head of Business Development for EuropeNews
Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe.READ MORE
Comments | 0 ADD COMMENT
10th International Conference on Mass Spectrometry and Chromatography
Oct 08 - Oct 09, 2018